Formoterol
Highest phase reached
Approved
Drug type
Small molecule
First approval year
2001
- First approval year
- 2001
- Listing at source
- Listed
- Highest phase reached
- Approved
- Drug type
- Small molecule
- Drug name
- Formoterol
- Molecular weight
- 344.41
- Structure (SMILES)
- COc1ccc(CC(C)NCC(O)c2ccc(O)c(NC=O)c2)cc1
- oxis
- Oxis
- eformoterol
- EFORMOTEROL
- formoterol
- Formoterol
- FORMOTEROL [HSDB]
- formoterol [INN]
- FORMOTEROL [MI]
- FORMOTEROL [VANDF]
- Formoterol [WHO-DD]
- formoterol hsdb
- formoterol inn
- formoterol mi
- formoterol vandf
- formoterol who dd
- oxis
- Oxis
- CAS registry numbers
- 73573-87-2
- ChEMBL ID
- CHEMBL1256786
- InChIKey
- BPZSYCZIITTYBL-UHFFFAOYSA-N
- PubChem compound IDs
- 3410
- RxNorm IDs (RxCUI)
- 25255
- FDA ingredient codes (UNII)
- 5ZZ84GCW8B
- R03AC13
- R03CC15
Sources for recorded values
- Applicant
- ASTRAZENECA AB
- Approval date
- 23 Jul 2020
- Application number
- NDA212122
- Patents
- 9
- Designations
- 0
- Earliest recorded loss of exclusivity
- 5 Oct 2038
- First in class
- No
- Fast track
- No
- Breakthrough designation
- No
- Orphan designation
- No
- Priority review
- No
- Orphan exclusivity
- No
- Accelerated approval
- No
- Availability
- Prescription only
- Pharmacology name
- formoterol
- Type
- Synthetic organic
- Drug name stem
- -terol
- Approval recorded by Guide to Pharmacology
- Yes
Administration routes
- topical
- Action
- Agonist
- Action type
- Agonist
- Target
- β2-adrenoceptor
- Gene symbol
- ADRB2
- Protein identifier
- P07550
- Affinity units
- pEC50
- Primary target
- Yes
- Action
- Agonist
- Action type
- Agonist
- Target
- β1-adrenoceptor
- Gene symbol
- ADRB1
- Protein identifier
- P08588
- Median affinity
- 8.3
- Affinity units
- pEC50
- Action
- Agonist
- Action type
- Agonist
- Target
- β1-adrenoceptor
- Gene symbol
- ADRB1
- Protein identifier
- P08588
- Affinity units
- pKi
Open Targets mechanisms
- Mechanism
- Beta-2 adrenergic receptor agonist
- Action type
- Agonist
- Target
- Beta-2 adrenergic receptor
DrugCentral mechanisms
- Action type
- Agonist
- Gene symbol
- ADRB2
- Protein identifier
- P07550
- Organism
- Homo sapiens
- Target development level
- Clinical
- Condition
- Pulmonary Disease, Chronic Obstructive
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000341
- Subject identifier
- D029424
- Condition
- Emphysema
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000464
- Subject identifier
- D004646
- Condition
- Bronchiolitis Obliterans
- Highest recorded phase
- 2
- Condition identifier
- EFO:0007183
- Subject identifier
- D001989
- Condition
- Bronchitis
- Highest recorded phase
- 3
- Condition identifier
- EFO:0009661
- Subject identifier
- D001991
- Condition
- Respiratory Distress Syndrome
- Highest recorded phase
- 2
- Condition identifier
- EFO:1000637
- Subject identifier
- D012128
- Condition
- Bronchiectasis
- Highest recorded phase
- 3
- Condition identifier
- HP:0002110
- Subject identifier
- D001987
- Condition
- Lung Diseases, Obstructive
- Highest recorded phase
- 4
- Condition identifier
- HP:0006536
- Subject identifier
- D008173
- Condition
- Alzheimer Disease
- Highest recorded phase
- 2
- Condition identifier
- MONDO:0004975
- Subject identifier
- D000544
- Condition
- Asthma
- Highest recorded phase
- 3
- Condition identifier
- MONDO:0004979
- Subject identifier
- D001249
- Condition
- Hypersensitivity
- Highest recorded phase
- 2
- Condition identifier
- MONDO:0005271
- Subject identifier
- D006967
- Condition
- Severe Acute Respiratory Syndrome
- Highest recorded phase
- 2
- Condition identifier
- MONDO:0100096
- Subject identifier
- D045169
- Condition identifier
- EFO_0000319
- Condition identifier
- EFO_0000341
- Condition identifier
- EFO_0000464
- Highest recorded phase
- 3
- Condition identifier
- EFO_0007183
- Highest recorded phase
- 2
- Condition identifier
- EFO_0009837
- Condition identifier
- EFO_0022917
- Condition identifier
- EFO_1000637
- Highest recorded phase
- 2
- Condition identifier
- HP_0001943
- Condition identifier
- HP_0006536
- Condition identifier
- HP_0006536
- Highest recorded phase
- 4
- Condition identifier
- HP_0012735
- Condition identifier
- MONDO_0004822
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0004849
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0004975
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0004979
- Condition identifier
- MONDO_0004979
- Highest recorded phase
- 4
- Condition identifier
- MONDO_0005002
- Highest recorded phase
- 4
- Condition identifier
- MONDO_0005147
- Condition identifier
- MONDO_0005271
- Condition identifier
- MONDO_0008903
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0013730
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0015265
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0100096
- Condition identifier
- MONDO_0100096
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0100233
- Event
- adrenal cortex necrosis
- Reports
- 5
- Reporting signal score
- 34.4
- Event
- adrenal insufficiency
- Reports
- 8
- Reporting signal score
- 14.1815
- Event
- adrenal mass
- Reports
- 3
- Reporting signal score
- 10.693
- Event
- anosmia
- Reports
- 6
- Reporting signal score
- 13.2301
- Event
- asthma
- Reports
- 168
- Reporting signal score
- 536.925
- Event
- asthma-chronic obstructive pulmonary disease overlap syndrome
- Reports
- 7
- Reporting signal score
- 36.8492
- Event
- atrial enlargement
- Reports
- 9
- Reporting signal score
- 50.8256
- Event
- blood count abnormal
- Reports
- 17
- Reporting signal score
- 37.3328
- Event
- breath sounds abnormal
- Reports
- 11
- Reporting signal score
- 34.4173
- Event
- bronchial hyperreactivity
- Reports
- 8
- Reporting signal score
- 31.9318
- Event
- bronchial obstruction
- Reports
- 9
- Reporting signal score
- 35.3706
- Event
- bronchiectasis
- Reports
- 10
- Reporting signal score
- 26.4195
- Event
- bronchopulmonary aspergillosis allergic
- Reports
- 3
- Reporting signal score
- 11.1969
- Event
- bronchospasm
- Reports
- 8
- Reporting signal score
- 11.0515
- Event
- candida infection
- Reports
- 8
- Reporting signal score
- 14.385
- Event
- cardiac failure chronic
- Reports
- 9
- Reporting signal score
- 28.163
- Event
- cardiac murmur
- Reports
- 6
- Reporting signal score
- 10.5572
- Event
- chest discomfort
- Reports
- 26
- Reporting signal score
- 29.1667
- Event
- chronic obstructive pulmonary disease
- Reports
- 53
- Reporting signal score
- 138.267
- Event
- chronic sinusitis
- Reports
- 9
- Reporting signal score
- 29.3346
- Event
- cockroach allergy
- Reports
- 4
- Reporting signal score
- 28.6672
- Event
- congenital pneumonia
- Reports
- 3
- Reporting signal score
- 15.2657
- Event
- coronary artery stenosis
- Reports
- 11
- Reporting signal score
- 28.797
- Event
- cough
- Reports
- 62
- Reporting signal score
- 69.8708
- Event
- craniosynostosis
- Reports
- 3
- Reporting signal score
- 10.1131
And 80 more, listed on the interactive page.
- NCT00130351
- NCT00235911
- NCT00238784
- NCT00242775
- NCT00244608
- NCT00252785
- NCT00252824
- NCT00255255
- NCT00259766
- NCT00259792
- NCT00288379
- NCT00290264
- NCT00314509
- NCT00319306
- NCT00326053
- NCT00381485
- NCT00385593
- NCT00413387
- NCT00419757
- NCT00419952
- NCT00424008
- NCT00443482
- NCT00449501
- NCT00449527
- NCT00497237
And 109 more, listed on the interactive page.
- Dose
- 20mcg
- Route
- Inhalation
- How often
- Twice daily
Conditions of use
- Use with a standard jet nebulizer connected to an air compressor
- Hydrogen bond acceptors
- 5
- Hydrogen bond donors
- 4
- Polar surface area
- 90.82
- Calculated partition coefficient (ALogP)
- 2.22
- Calculated partition coefficient (XLogP)
- 1.8
- Prodrug
- No
- Chirality
- Racemic
- Inorganic
- No
- Rule-of-five violations
- 0
- Rotatable bonds
- 9
- Heavy atoms
- 25
- Molecular formula
- C19H24N2O4
- Monoisotopic mass
- 344.17360725
- Natural product
- Yes
- 0310-4616
- 0310-6616
- Recorded assays
- 249
- Active assays
- 47
- Confirmatory
- Other
- Bronchodilator Agents
- Adrenergic beta-2 Receptor Agonists
These details could not be displayed.
Related records
Trials (244)
- 26 Week Efficacy, Safety and Tolerability Study of Indacaterol in Patients With Chronic Obstructive Pulmonary Disease (COPD)
- A 1-year Multi-center, Prospective, Cohort Study in Patients With Chronic Obstructive Pulmonary Disease Treated With Long-acting Bronchodilator
- A 42-day Parallel Group Safety Study of Revefenacin and Formoterol, Administered in Sequence and as a Combination, in Participants With COPD
- A Bioequivalence Pivotal Study of SYN010 HFA Inhaler and Symbicort® 160/4.5 in Healthy Volunteers With Charcoal Block
- A Bioequivalence Pivotal Study of SYN010 HFA Inhaler and Symbicort® 160/4.5 in Healthy Volunteers Without Charcoal Block
- A Clinical Study to Evaluate Symbicort Turbuhaler Used 'as Needed' in Adults and Adolescents With Asthma
- A Clinical Study to Evaluate Symbicort Turbuhaler Used 'as Needed' in Adults and Adolescents With Asthma.
- A Clinical Trial Comparing TQC3927 Inhaled Powder With Glycopyrronium Bromide and Formoterol Inhaled Aerosol (Biovoping® Lingchang®) for the Treatment of Chronic Obstructive Pulmonary Disease
- A Comparative Study Between Foraseq and Formoterol/Budesonide Inhalation Capsules in Patients with Asthma
- A Comparison of Symbicort® pMDI 2 x 160/4.5 μg Bid and 2 x 80/4.5 μg Bid With Formoterol Turbuhaler® 2 x 4.5 μg Bid and Placebo in Patients With COPD
- A Comparison of Symbicort® pMDI 2 x 160/4.5 μg Bid and Symbicort® pMDI 2 x 80/4.5 μg Bid With Formoterol Turbuhaler®, Budesonide pMDI, the Combination of Formoterol Turbuhaler® and Budesonide pMDI, and Placebo in COPD Patients
- A Comparison of SYMBICORT® pMDI With Formoterol Turbuhaler® in Subjects With COPD
- A Comparison of the Control of Asthma Provided by Symbicort® Turbuhaler® Versus Symbicort® Turbuhaler® Plus Pulmicort® Turbuhaler® Plus Terbutaline Turbuhaler®
- A Comparison Study Between the Fixed Dose Triple Combination of Fluticasone Furoate/ Umeclidinium/ Vilanterol Trifenatate (FF/UMEC/VI) With Budesonide/Formoterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
- A Crossover Study in the Treatment of Patients With COPD
- A Dose Ranging Study With CHF 1531 in Subjects With Asthma (FLASH)
- A Dose Ranging Trial of 4 Doses of Indacaterol Delivered Via the TWISTHALER® Device in Patients With Chronic Obstructive Pulmonary Disease (COPD)
- A Dose Ranging Trial of 4 Doses of Indacaterol Delivered Via TWISTHALER® Device in Adult and Adolescent Patients With Persistent Asthma
- A Drug Utilisation Post-authorisation Study of New Users of Aclidinium Bromide (Monotherapy or in Combination)
- A Guideline Approach to Therapy Step-down Utilising Flutiform Change and Step-down
Approved for (1)
- Obstructive lung disease
In development for (10)
- Acute respiratory distress syndrome Phase 2
- Allergic disease Phase 2
- Alzheimer disease Phase 2
- Asthma Phase 3
- Bronchiectasis Phase 3
- Bronchiolitis obliterans syndrome Phase 2
- Bronchitis Phase 3
- Chronic obstructive pulmonary disease Phase 3
- COVID-19 Phase 2
- Pulmonary emphysema Phase 3
Other linked conditions (2)
- Cardiovascular disorder
- Type 1 diabetes mellitus
Targets (1)
- ADRB2 Beta-2 adrenergic receptor agonist